TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03687229

Intervention type: DIAGNOSTIC_TEST
Intervention: A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)
Description: measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction

Intervention type: DIAGNOSTIC_TEST
Intervention: A)microribonucleic acid-122(miRNA-122), B) Hepatitis C virus Real Time Polymerase chain Reaction (HCV RT-PCR)
Description: measure level of serum micro ribonucleic acid -122 and insulin resistance in chronic hepatitis C patients using real time polymerase chain reaction

Intervention type: DIAGNOSTIC_TEST
Intervention: A)fasting serum glucose, B)Fasting serum insulin
Description: measure level of insulin resistance

Intervention type: DIAGNOSTIC_TEST
Intervention: A)fasting serum glucose, B)Fasting serum insulin
Description: measure level of insulin resistance
Study: NCT00566475

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: telemedicine
Description: School telemedicine intervention involving school personnel, the child with type 1 diabetes and at least 1 parent
Study: NCT02205229

Intervention type: DRUG
Intervention: Multi-ingredient, topical compounded medications
Study: NCT05246735

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: MR-guided Near Infrared optical tomography
Study: NCT00270816

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon-ß-1b
Description: 250 micrograms (8 MIU) administered subcutaneously (sc) every other day with a discontinuance month every 2 months

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon ß-1b
Description: 250 micrograms (8 MIU) administered subcutaneously (sc) every other day
Study: NCT04390334

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Daridorexant
Description: Daridorexant will be administered orally as 1 film-coated tablet of 50 mg strength to be taken in the morning under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Famotidine will be administered orally as 1 film-coated tablet of 40 mg strength to be taken in the morning under fasted conditions.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz
Description: Efavirenz will be administered orally as 1 film-coated tablet of 600 mg strength o.d. in the evening.
Study: NCT03949816

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical consultation: different doctor-patient-centered style of communication
Description: Different doctor-patient communication

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: medical consultation: different doctor-patient-centered style of communication
Description: Different doctor-patient communication

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: information letter / no medical consultation
Description: In the control treatment participants receive all information about the herbal medical product in an information letter but have no contacted with the simulated doctor.
Study: NCT03026556

Intervention type: DRUG
Intervention: Dabigatran vs. Rivaroxaban
Description: observed for 6 years

Intervention type: DRUG
Intervention: Dabigatran vs. Apixaban
Description: Observed for 6 years
Study: NCT02907866

Intervention type: DEVICE
Intervention: Ultrasound with EBUS scope and with linear ultrasound probe
Description: All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.

Intervention type: DEVICE
Intervention: Ultrasound with EBUS scope and with linear ultrasound probe
Description: All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.

Intervention type: DEVICE
Intervention: Ultrasound with EBUS scope and with linear ultrasound probe
Description: All subjects will have an ultrasound of the chest performed with the tip of the EBUS scope as well as the linear ultrasound probe, which will be used as a reference for comparison. At the end of the procedure, while the patient in the supine position, the transducer of the EBUS bronchoscope will be placed on the anterior thorax, superficial to the skin and in a sagittal direction that is perpendicular to 2 ribs. The depth of the ultrasound beam will be increased to identify the pleural sliding sign and B lines (vertical lines) when present.This will be followed by use of linear ultrasound probe to scan the chest wall for normal lung sliding, B-lines and potential pneumothorax. The patient will remain in supine position. The linear probe will be placed on anterior thorax at the level of second intercostal space. The depth of the ultrasound beam will be adjusted to identify lung sliding and B-lines.
Study: NCT01597076

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: iridoid enriched mixed fruit beverage
Description: Mixed fruit beverage consisting of noni (Morinda citrifolia) juice, Cornelian cherry (Cornus mas \& Cornus officinalis) puree and juice, olive (Olea europea) leaf extract, and other fruit juices and natural flavors
Study: NCT01450566

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine
Description: Use of lidocaine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: Saline
Study: NCT03288558

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: A comprehensive perioperative mechanical ventilation strategy
Description: 1) Intervention group.~* Recruitment maneuvers (doubling the tidal volumes for 10 consecutive breaths) every 30min and after every time mechanical ventilation is stopped for surgical reasons, suctioning occurs or the breathing circuit is disconnected~* Mechanical ventilation will be continued during CPB (PEEP 5 cm H2O, respiratory rate 8/min, Tidal Volume 6 ml/kg PBW, FiO2 21%~* Avoidance of lung de-recruitment during patient's transfer (use of PEEP via PEEP valves, endotracheal tube clamps during disconnection from the breathing circuit)~* Avoidance of disconnection from respiratory circuit during respiratory secretions suctioning (applying closed suction circuits)~* For the remaining aspects the mechanical ventilation settings will be the same as in the control group.~Tidal volume 6ml/kg PBW PEEP 5cm H20 FiO2 to target SatO2 of 92-97% Discontinuation of mechanical ventilation during cardiopulmonary bypass
Study: NCT03986671

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transmembrane EMG Oropharynx Probe
Description: Examination of the electromyographic signal from oropharyngeal muscles obtained using an investigational transmembrane sensor attached to a rigid probe and an FDA-approved very fine concentric needle electrode (Ambu Neuroline 25 mm x 30G).
Study: NCT04399434

Intervention type: OTHER
Intervention: test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity
Description: test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers

Intervention type: OTHER
Intervention: test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity
Description: test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers

Intervention type: OTHER
Intervention: test gut microbiota, SCFAs and glucolipid metabolism and insulin sensitivity
Description: test gut microbiota and SCFAs in mothers and their newborns and glucolipid metabolism and insulin sensitivity in mothers
Study: NCT02132312

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OMS302

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenylephrine HCl
Study: NCT02860572

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: follow-up without intervention

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: fluid bolus
Study: NCT03229668

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Placebo oral capsule administered 1 hour prior to the surgical operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Oral Capsule [Lyrica] 75mg
Description: Pregabalin Oral Capsule \[Lyrica\] 75 mg administered 1 hour prior to the surgical operation

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pregabalin Oral Capsule [Lyrica] 150 mg
Description: Pregabalin Oral Capsule \[Lyrica\] 150 mg administered 1 hour prior to the surgical operation
Study: NCT03683758

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FIFA11+
Description: The FIFA11+ has three parts and consist of 15 exercises.~Part 1 consists of active stretching, running and controlled partner contact drills.~Part 2 has three difficulty levels for 6 sets of exercises. The exercises consist of core and leg strength exercises, balance and plyometric drills. The exercises in this section are perhaps the most unique element to the FIFA11+ warm-up, as strength-specific exercises like the Nordic Hamstring Curl are not generally included in soccer warm-ups.~Part 3 consists of higher intensity running drills, compared to those covered in Part 1.~Unlike many soccer warm-ups, the FIFA11+ has been studied rigorously in terms of its injury reduction potential.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 'Usual' Soccer Warm-up
Description: This warm-up is time-matched to the FIFA11+ (approximately 20 minutes) and is considered 'usual' for the team.~This warm-up consists of stretching, running and agility drills, in addition to small sided games with a soccer ball, which is not a part of the FIFA11+.~The 'usual' warm-up is decided by the coach with no standardization nor any formal research on its effectiveness in injury reduction or performance enhancement.
Study: NCT04594928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: GLPG3667 capsules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GLPG3667
Description: GLPG3667 capsules

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules
Study: NCT04241263

Intervention type: DEVICE
Group type: OTHER
Intervention: Wireless vital sign monitoring - comparative
Description: Participants who currently have vital sign monitoring will, in addition, have the wireless system attached. We will then collect up to 24 hours of vital sign data from both systems, which will allow us to make direct comparisons between them.

Intervention type: DEVICE
Group type: OTHER
Intervention: Wireless vital sign monitoring - usability
Description: Babies will be recruited who do not currently require vital sign monitoring. The wireless system will be attached to these babies by nurses who have been trained in its use. A parent will then be asked to perform Kangaroo Care for as long as they feel comfortable. After the baby is placed back in its cot, and the sensors have been removed, we will conduct (separate) interviews with the nurse and the parent on the neonatal intensive care unit (NICU).
Study: NCT00619307

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif New Formulation + prophylactic Ibuprofen
Description: Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, receives systematically 400 mg ibuprofen as prophylactic treatment against flu-like symptoms on days when Rebif New Formulation 44 mcg three times a week is injected

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rebif New Formulation + ibuprofen PRN
Description: Subjects, currently on Rebif® 44 mcg three times a week, using Rebiject II as an injection device and having received Rebif® full dose 44 mcg three times a week for at least 6 months, should not administer Ibuprofen before the first Rebif New Formulation injection. If flu-like symptoms occur after the 44 mcg Rebif New Formulation injection then the subject can administer 400 mg ibuprofen. This should only be administered after the Rebif New Formulation injection and not before the Rebif New Formulation injection.
Study: NCT02215304

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium longum ssp infantis R0033
Description: 12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lactobacillus helveticus R0052
Description: 12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bifidobacterium bifidum R0071
Description: 12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 12 weeks intervention study: A run-in period of two weeks, 8 weeks of intervention (from weeks 2 to 10) and two weeks after intervention finishing time.~During the 8 weeks of intervention participants will intake one daily dose of the product which contains 3\*10E9 colony forming units (CFU)
Study: NCT01781559

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: phenolic acid
Description: phenolic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: phenolic acid
Description: phenolic acid

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: phenolic acid
Description: phenolic acid
Study: NCT01835730

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PE0139 Injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02157077

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aflibercept
Description: Intravitreal Injection
Study: NCT03890367

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid Conjugate vaccine
Description: Pharmaceutical form: Liquid solution for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal polysaccharide group A, C, W-135 and Y Conjugate vaccine
Description: Pharmaceutical form: Powder and solvent for suspension for injection Route of administration: Intramuscular

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Meningococcal group C polysaccharide Conjugate vaccine adsorbed
Description: Pharmaceutical form: Suspension for injection Route of administration: Intramuscular
Study: NCT02123576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxyfylline

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AMO Therapy
Description: Albumin, midodrine and octreotide therapy (standard of care for HRS)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMO Therapy
Description: Albumin, midodrine and octreotide therapy (standard of care for HRS)
Study: NCT03586115

Intervention type: DEVICE
Intervention: Critical flicker frequency assessment
Description: All patients will undergo critical flicker frequency assessment to evaluate the presence of minimal hepatic encephalopaty. In addition, hepatic elastometry will be assessed to evaluate the presence of advanced liver fibrosis.
Study: NCT02386501

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS31-164
Study: NCT00997594

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency ablation
Description: Radiofrequency (RF) ablation was done after RF electrodes were placed in the adrenal tumor in the adrenal RF ablation group. RF ablation was done after RF electrodes were placed in the targeted abdominal tumors other than adrenal gland in the abdominal RF ablation other than adrenal gland group.
Study: NCT03172130

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Straight CPAP

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham CPAP
Study: NCT01515813

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium
Description: One 40 mg tablet of Pravastatin sodium taken orally once daily.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Description: Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Description: Participant will be administered one tablet of Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate (EFV/FTC/TDF)600 mg/200 mg/300 mg taken orally once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pravastatin sodium
Description: Two 40mg tablets (80 mg total) of Pravastatin sodium taken orally once daily.
Study: NCT01579630

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500mg/m2 iv
Description: EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed 500mg/m2 iv and Gefitinib 250 mg
Description: EGFR mutation negative patients who continuously respond (CR, PR or SD) to the 4th cycle of pemetrexed/ cisplatin or pemetrexed/carboplatin will be randomized in a 1:1 ratio to receive either gefitinib/ pemetrexed, or pemetrexed alone as maintenance therapy until progression of disease (PD) or discontinuation of treatment for other reasons.
Study: NCT03667690

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rezafungin for Injection
Description: Intravenous antifungal therapy
Study: NCT03252730

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: WO 4260 Cosmetic Product for Topical Use
Description: Application on the hair scalp at least once a day over four weeks
Study: NCT02027532

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin
Study: NCT03667690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Caspofungin
Description: Intravenous antifungal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluconazole
Description: Oral antifungal therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous placebo
Description: Normal saline

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral placebo
Description: Microcrystalline cellulose
Study: NCT00528996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR
Description: Solution
Study: NCT03720470

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injectable Placebo
Description: Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Injectable Placebo
Description: Two subcutaneous injections of Placebo (for Dupilumab) administered as a loading dose on Day 1 followed by one injection every other week (q2w) until Week 16.
Study: NCT00528996

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR
Description: Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEA 2180 BR
Description: Solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tiotropium Bromide
Description: Solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution